Follow
Suzanne Garland
Suzanne Garland
Royal Women's Hospital
Verified email at thewomens.org.au
Title
Cited by
Cited by
Year
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study
S de Sanjose, WGV Quint, L Alemany, DT Geraets, JE Klaustermeier, ...
The lancet oncology 11 (11), 1048-1056, 2010
28652010
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
SM Garland, M Hernandez-Avila, CM Wheeler, G Perez, DM Harper, ...
New England Journal of Medicine 356 (19), 1928-1943, 2007
24802007
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a …
J Paavonen, P Naud, J Salmerón, CM Wheeler, SN Chow, D Apter, ...
The Lancet 374 (9686), 301-314, 2009
20622009
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
EA Joura, AR Giuliano, OE Iversen, C Bouchard, C Mao, J Mehlsen, ...
New England Journal of Medicine 372 (8), 711-723, 2015
15962015
Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis
DA Machalek, M Poynten, F Jin, CK Fairley, A Farnsworth, SM Garland, ...
The lancet oncology 13 (5), 487-500, 2012
10792012
A review of clinical trials of human papillomavirus prophylactic vaccines
JT Schiller, X Castellsagué, SM Garland
Vaccine 30, F123-F138, 2012
9022012
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double …
M Lehtinen, J Paavonen, CM Wheeler, U Jaisamrarn, SM Garland, ...
The lancet oncology 13 (1), 89-99, 2012
8882012
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence
CS Bradshaw, AN Morton, J Hocking, SM Garland, MB Morris, LM Moss, ...
The Journal of infectious diseases 193 (11), 1478-1486, 2006
8462006
Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined …
EA Joura, S Leodolter, M Hernandez-Avila, CM Wheeler, G Perez, ...
The Lancet 369 (9574), 1693-1702, 2007
8362007
Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis
M Drolet, É Bénard, N Pérez, M Brisson, H Ali, MC Boily, V Baldo, ...
The Lancet 394 (10197), 497-509, 2019
8282019
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in …
DR Brown, SK Kjaer, K Sigurdsson, OE Iversen, M Hernandez-Avila, ...
The Journal of infectious diseases 199 (7), 926-935, 2009
6972009
Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine
SM Garland, M Steben, HL Sings, M James, S Lu, R Railkar, E Barr, ...
The Journal of infectious diseases 199 (6), 805-814, 2009
6102009
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis …
CM Wheeler, X Castellsagué, SM Garland, A Szarewski, J Paavonen, ...
The lancet oncology 13 (1), 100-110, 2012
6092012
Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience
SM Garland, SK Kjaer, N Muñoz, SL Block, DR Brown, MJ DiNubile, ...
Reviews of Infectious Diseases 63 (4), 519-527, 2016
5772016
Web-based recruiting for health research using a social networking site: an exploratory study
Y Fenner, SM Garland, EE Moore, Y Jayasinghe, A Fletcher, SN Tabrizi, ...
Journal of medical Internet research 14 (1), e20, 2012
5042012
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women
N Muñoz, SK Kjaer, K Sigurdsson, OE Iversen, M Hernandez-Avila, ...
Journal of the National Cancer Institute 102 (5), 325-339, 2010
4752010
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial
WK Huh, EA Joura, AR Giuliano, OE Iversen, RP de Andrade, KA Ault, ...
The Lancet 390 (10108), 2143-2159, 2017
4582017
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions
SK Kjaer, K Sigurdsson, OE Iversen, M Hernandez-Avila, CM Wheeler, ...
Cancer prevention research 2 (10), 868-878, 2009
4172009
Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data
EA Joura, SM Garland, J Paavonen, DG Ferris, G Perez, KA Ault, WK Huh, ...
Bmj 344, 2012
4072012
Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional …
S de Sanjose, WG Quint, L Alemany, DT Geraets, JE Klaustermeier, ...
Lancet Oncol 11 (11), 1048-1056, 2010
3892010
The system can't perform the operation now. Try again later.
Articles 1–20